Albireo Pharma, Inc. (ALBO) SEC Filing 8-K Material Event for the period ending Wednesday, March 6, 2019

Albireo Pharma, Inc.

CIK: 1322505 Ticker: ALBO

View differences made from one to another to evaluate Albireo Pharma, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Albireo Pharma, Inc..


Assess how Albireo Pharma, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Albireo Pharma, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools
Ticker: ALBO
CIK: 1322505
Form Type: 8-K Corporate News
Accession Number: 0001104659-19-013162
Submitted to the SEC: Wed Mar 06 2019 5:28:04 PM EST
Accepted by the SEC: Wed Mar 06 2019
Period: Wednesday, March 6, 2019
Industry: Pharmaceutical Preparations
  1. Ending Agreement
  2. New Agreement

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: